Cargando...
Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda
To screen for drug resistance and possible treatment with Dolutegravir (DTG) in treatment-naive patients and those experiencing virologic failure during first-, second-, and third-line combined antiretroviral therapy (cART) in Uganda. Samples from 417 patients in Uganda were analyzed for predicted d...
Guardado en:
| Publicado en: | AIDS Res Hum Retroviruses |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Mary Ann Liebert, Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5934975/ https://ncbi.nlm.nih.gov/pubmed/29353487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2017.0205 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|